← Back to Search

Monoclonal Antibodies

Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel for Gastric Cancer

Phase 2
Waitlist Available
Research Sponsored by Pieris Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a new treatment called cinrebafusp alfa combined with other cancer drugs in patients with stomach or GEJ cancer. It targets a protein called HER2 to help the immune system destroy cancer cells.

Eligible Conditions
  • HER2 Positive Gastric Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Cinrebafusp alfa (PRS-343) in combination with tucatinibExperimental Treatment1 Intervention
Patients aged 18 years or older with HER2 low (IHC 1+ or IHC 2+ without HER2/neu amplification) gastric or GEJ adenocarcinoma who have received at least one prior treatment regimen
Group II: Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxelExperimental Treatment1 Intervention
Patients aged 18 years or older with HER2-positive gastric or GEJ adenocarcinoma who have progressed on prior treatment with a regimen containing a platinum and fluoropyrimidine and a HER2-directed therapy such as trastuzumab and now are candidates for treatment with ramucirumab and paclitaxel

Find a Location

Who is running the clinical trial?

Pieris Pharmaceuticals, Inc.Lead Sponsor
3 Previous Clinical Trials
171 Total Patients Enrolled
Tim Demuth, MD, PhDStudy DirectorPieris Pharmaceuticals, Inc.
1 Previous Clinical Trials
45 Total Patients Enrolled
Gordon Otto, MD, PhDStudy DirectorPieris Pharmaceuticals, Inc.
~20 spots leftby Dec 2025